Distributor inventory | Tablet

Type 2 diabetes mellitus (adjunct to diet and exercise) to improve post-meal and overall blood glucose control

Voglibose is an alpha-glucosidase inhibitor that delays digestion and absorption of carbohydrates in the intestine, reducing post-meal blood sugar spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, helping the body use glucose more effectively.

Oral tablet. Usually taken with meals; voglibose-containing tablets are typically taken just before or with the first bite of food. Take as prescribed by the doctor; swallow with water and do not crush unless advised. If a dose is missed, take it with the next meal; do not double the dose.

Flatulence, abdominal discomfort, diarrhea, nausea, vomiting, loss of appetite, metallic taste, headache

For prescription use. Not recommended in type 1 diabetes or diabetic ketoacidosis. Use with caution in kidney disease, liver disease, elderly patients, dehydration, and conditions predisposing to hypoxia; metformin can rarely cause lactic acidosis (seek urgent care for rapid breathing, severe weakness, abdominal pain, or drowsiness). Voglibose may cause gastrointestinal side effects and should be used cautiously in patients with intestinal disorders (e.g., obstruction, inflammatory bowel disease). Monitor blood glucose and HbA1c; monitor renal function periodically. Risk of hypoglycaemia increases if used with insulin or sulfonylureas; carry glucose source and treat lows as advised.

Alcohol, insulin, sulfonylureas (e.g., glimepiride), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), cimetidine, diuretics, corticosteroids, thyroid hormones, sympathomimetics

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Voglibose + Metformin tablets (other brands): Vobose M 0.3, Voglitor M 0.3, Voglimet 0.3, Vogli-M 0.3, Glyciphage-V 0.3